336 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22679 | Platinium resistant | Joseph Kerger | Ovary | Lilly | I4D-MC-JTJN | Trial closed | A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer | joseph.kerger@hubruxelles.be | 2 | 2 | |
| 22625 | RECIST 1.1, after standard trerapy | Ahmad Hussein Awada | Multiple | Lilly | I7W-MC-JQBA | Trial closed | A Phase 1 Study of LY3127804 as Monotherapy and in Combination with Ramucirumab in Patients with Advanced Solid Tumors | ahmad.awada@hubruxelles.be | 1 | 1 | |
| 22733 | ER+/HER2-. Metastatic | Andrea Gombos | Breast | Oslo University Hospital | ICON | Trial closed | A randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer | accueil.oncologie@hubruxelles.be | 2 | 2 | |
| 22813 | c-Kit positive tumor or PDGFR positive | Thierry Gil | Multiple | AB Science | IJB_1841 | Trial closed | AB04030 : A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatment. | thierry.gil@hubruxelles.be | 3 | 3 | |
| 22846 | Non-metastatic breast cancer/At the end of active treatment | Isabelle Merckaert | Breast | IJB_2484 | Trial closed | Impact of attentional bias towards threat on fear of cancer recurrence in breast cancer survivor | isabelle.merckaert@hubruxelles.be | ||||
| 22847 | Women treated for a non-metastatic breast cancer. At the end of active treatment (i.e. surgery, chemotherapy, radiotherapy). Experiencing moderate to high emotion dysregulation | Isabelle Merckaert | Breast | Institut Jules Bordet | IJB_2600 | Trial open for recruitment | Improving emotion regulation at the end of cancer treatment : A randomized controlled study assessing the impact of a multi-component psychological group intervention | isabelle.merckaert@hubruxelles.be | |||
| 22773 | after two lines, RECIST 1.1 | Ahmad Hussein Awada | Breast | Nektar Therapeutics | IJB_2655 | Trial closed | A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and Capecitabine | ahmad.awada@hubruxelles.be | 3 | 3 | |
| 22650 | vaccine, diarrhea, clostridium | Multiple | Pfizer | IJB_2672 | Trial closed | A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A Clostridium Difficile Vaccine In Adults 50 Years Of Age And Older | 3 | 3 | |||
| 22644 | second line metastatic | Liver | Incyte Corporate | IJB_2674 | Trial closed | A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy | 2 | 2 | |||
| 22654 | "Adjuvant", healthy margin | Spyridon Sideris | Kidney | BMS - Bristol Myers Squibb int. | IJB_2691 | Trial closed for recruitment | Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse | spyridon.sideris@hubruxelles.be | 3 | 3 | |
| 22628 | Reduced left ventricular ejection fraction | Thierry Berghmans | Lung | Institut Jules Bordet | IJB_2707 | Trial closed | Cardiovascular morbidities and lung cancer treatment : a prospective registry | ||||
| 22850 | Metastatic, any tumors | Solid tumors | Institut Jules Bordet | IJB_2728 | Trial open for recruitment | Improving emotion regulation for patients with metastatic cancer: A pilot study assessing the impact of a multi-component psychological group intervention | |||||
| 22657 | Metastatic, Biopsy mandatory | Nuria Kotecki | Multiple | Lilly | IJB_2732 | Trial closed | A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination with Anti-PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors | Nuria.Kotecki@hubruxelles.be | 1/1b | 1 | |
| 22633 | Metastatic, first line, RECIST 1.1 | Philippe Aftimos | Breast | Servier | IJB_2743 | Trial closed | Phase I/II trial of S81694 administered intravenously in combination with paclitaxel to evaluate the safety, pharmacokinetic and efficacy in metastatic breast cancer | philippe.aftimos@hubruxelles.be | 1 | 1 |